Chronotherapy with finasteride in patients with androgenetic alopecia

Chronotherapy with finasteride in patients with androgenetic alopecia - Chronotherapy with finasteride

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009623

Enrollment

Registered

2012-12-26

Start date

2013-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

androgenetic alopecia

Interventions

Dosing of finasteride in the morning for 12 months Dosing of finasteride in the evening for 12 months Dosing of finasteride in the evening for 6 months, and thereafter dosing in the morning for 6 mont

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) Patients with androgenetic alopecia 2) Patients who have been treated with finasteride (a fixed dosage in the morning) for more than 6 months 3) All concomitant disease are stable 4) Patients who can give written informed consent

Exclusion criteria

Exclusion criteria: 1) Patients with hypersensitivity to the drug contents 2) Female 3) Acute diseases treated with medication(s) during the 1 month 4) Patients who are disqualified by the doctor

Design outcomes

Secondary

Measure	Time frame
All laboratory abnormalities All adverse events Compliance with treatment Self-assessment of the drug efficacy against alopecia Self-assessment of the drug effect on libido	—

Primary

Measure	Time frame
Changes in liver function tests Changes in prostate-specific antigen level	—

Countries

Japan

Contacts

Public ContactHitoshi Ando

Jichi Medical University Clinical Pharmacology

h-ando@jichi.ac.jp0285-58-7388

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026